Drugs / pegylated IFN
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02690103 Comparator | Jul 2012 → Jun 2015 | chronic hepatitis C virus infection | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT01664845 Comparator | Aug 2012 → Aug 2014 | chronic hepatitis C virus infection | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated IFN | “Drug: pegylated-IFN” NCT01664845 ↗ |
| Known as | Pegasys-Roche | “Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.” NCT02690103 ↗ |
| Route | Subcutaneous | “Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.” NCT02690103 ↗ |